Initial experience with conservative treatment in cancer patients with osteonecrosis of the jaw (ONJ) and predictors of outcome
Faculty of Medicine and Health Sciences
Annals of oncology / European Society for Medical Oncology. - Amsterdam
, p. 331-336
University of Antwerp
Background: Overall survival (OS) and outcome of cancer patients with bisphosphonate-associated osteonecrosis of the jaw (ONJ) using conservative treatment (chlorhexidine 0.12% rinse, intermittent antibiotics, and careful sequestrectomy) are unknown. Design: In all, 33 ONJ patients were studied for OS and ONJ outcome. Results: Median duration of bisphosphonate treatment was 27 months (range 4115) and was stopped in 25 (76%) patients. Nine (27%) cases presented with stage 1, 21 (64%) with stage 2, and 3 (9%) with stage 3 disease. During median follow-up of 23 months, 11 patients (33%) died (median survival 39 months), with no ONJ-related fatalities. Out of 30 assessable patients, 53% no longer had exposed bone, 37% had stable lesions, and 10% showed progressive necrosis. The hazard ratio for healing with doubling of bisphosphonate exposure was 0.419 [95% confidence interval (CI) 0.1780.982; P = 0.045], stage 2 versus stage 1 disease 0.216 (95% CI 0.0630.738; P = 0.015), and stage 3 versus stage 1 disease 0.084 (95% CI 0.0080.913; P = 0.042). Cessation of bisphosphonate treatment did not influence outcome. Conclusions: Conservative treatment of ONJ leads to mucosal closure in 53% of patients. Doubling the exposure time to bisphosphonates and higher stages of ONJ significantly reduce ONJ healing rates.